GO
Loading...

Enter multiple symbols separated by commas

Stocks Amgen Inc

More

  • June 19- U.S. stock index futures were slightly higher on Friday, a day after the Nasdaq Composite index broke its last standing milestone from the dot-com era as it set a record intraday high. *San Francisco Fed president John Williams is due to speak before the National Bureau of Economic Research East Asian Seminar on Economics in San Francisco, while Cleveland...

  • June 18- Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy. The U.S. Food and Drug Administration approved Vectibix in 2006 as a standalone treatment for metastatic colorectal cancer. Colorectal cancer affects about 1.2 million people worldwide each year,...

  • June 18- Amgen Inc said its experimental cancer drug met its main goal of improving overall survival in patients with the third most common form of the disease.

  • Early movers: GE, GOOG, AMZN, NKE, M & more Thursday, 11 Jun 2015 | 10:00 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: Box, Krispy Kreme, Nike & more Wednesday, 10 Jun 2015 | 5:52 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Wednesday: Box, Krispy Kreme, Nike & more.

  • FDA panel backs Amgen cholesterol drug Wednesday, 10 Jun 2015 | 4:03 PM ET
    FDA panel backs Amgen cholesterol drug

    CNBC's Meg Tirrell reports the FDA panel has backed Amgen's cholesterol drug 11-4.

  • Why a FDA nod isn't enough for Regeneron shares Wednesday, 10 Jun 2015 | 12:49 PM ET
    A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, N.Y.

    Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • FDA panel backs first-in-class cholesterol drug Wednesday, 10 Jun 2015 | 8:44 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.

  • The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...

  • WASHINGTON, June 5- An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday before a meeting on Tuesday of a panel of outside advisers to the FDA who will discuss...

  • WASHINGTON, June 5- A drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday on the FDA's website before a meeting Tuesday of a panel of outside advisers who will discuss the drug...

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET
    Biotech

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • Early movers: TWC, AAPL, CTRP, CRM, GM & more Tuesday, 26 May 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.